HRS-7450 Injection

Phase 2

FFujian Shengdi Pharmaceutical Co., Ltd.

HRS-7450 Injection is one of 6 therapeutic programs targeting Acute Ischemic Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Ischemic StrokeActive, not recruiting

Acute Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Acute Ischemic Stroke

#DrugCompanyPhaseTrials

Low-Dose Tenecteplase Intravenous Thrombolysis

SSouthwest Hospital, China

Approved

1 2

Standard-Dose Tenecteplase Intravenous Thrombolysis

SSouthwest Hospital, China

Approved

1 3

Sovateltide

PPharmazz, Inc.

Phase 3

1 4

Prourokinase

SSuzhou Landing Pharmaceuticals

Phase 2

1 5

HRS-7450 Injection

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

1 6

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Acute Ischemic Stroke

NCT07233070

Clinical

Trials by Indication[1]

Acute Ischemic Stroke1 trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.

Active, not recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07233070·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HRS-7450 Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for HRS-7450 Injection. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fujian Shengdi Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: FFujian Shengdi Pharmaceutical Co., Ltd.

HRS-7450 Injection

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News